- Reports suggest Trump is planning to reclassify marijuana as a Schedule III drug from Schedule I, moving marijuana out of a group that includes heroin and placing it among the ranks of substances such as combination pain medications. Such a change would also alter the tax requirements for cannabis companies.
Reports emerged late on December 11, 2025, indicating President Donald Trump intends to issue an executive order directing federal agencies to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act.
This shift would acknowledge marijuana's accepted medical uses and lower abuse potential, while crucially allowing cannabis companies to deduct business expenses under Section 280E tax rules—currently a major profitability barrier. The news ignited sector-wide enthusiasm, with TLRY leading gains as investors anticipated improved financials and broader legitimacy for the industry. Trading volume spiked in after-hours, reflecting momentum from prior legislative buzz like the senator's cannabis bill earlier in the week, amplifying optimism amid ongoing U.S. reform discussions.


